Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Journal article published in 2020 by
Peter Alping 
,
Johan Askling ,
Joachim Burman,
Katharina Fink,
Anna Fogdell‐Hahn,
Martin Gunnarsson,
Jan Hillert,
Annette Langer‐Gould,
Jan Lycke,
Petra Nilsson,
Jonatan Salzer,
Anders Svenningsson,
Magnus Vrethem,
Tomas Olsson,
Fredrik Piehl
and other authors.
,
Johan Askling ,
Joachim Burman,
Katharina Fink,
Anna Fogdell‐Hahn,
Martin Gunnarsson,
Jan Hillert,
Annette Langer‐Gould,
Jan Lycke,
Petra Nilsson,
Jonatan Salzer,
Anders Svenningsson,
Magnus Vrethem,
Tomas Olsson,
Fredrik Piehl
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 